{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:24:31Z","timestamp":1791465871558,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.smim.2024.101863","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T15:31:12Z","timestamp":1706110272000},"page":"101863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond"],"prefix":"10.1016","volume":"72","author":[{"given":"Evangelos","family":"Andreakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2024.101863_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.smim.2024.101863_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1098\/rspb.1957.0049","article-title":"Virus interference. II. Some properties of interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.smim.2024.101863_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.725605","article-title":"Human leukocyte interferon purified to homogeneity","volume":"202","author":"Rubinstein","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101863_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1073\/pnas.76.2.640","article-title":"Human leukocyte interferon: production, purification to homogeneity, and initial characterization","volume":"76","author":"Rubinstein","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2024.101863_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type i and type iii interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2024.101863_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu Rev. Virol."},{"key":"10.1016\/j.smim.2024.101863_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.smim.2024.101863_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2018.10.007","article-title":"Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control","volume":"56","author":"Andreakos","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01232","article-title":"Interferon-lambdas: front-line guardians of immunity and homeostasis in the respiratory tract","volume":"8","author":"Andreakos","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","article-title":"Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness","volume":"46","author":"Galani","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2024.101863_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/emmm.201100142","article-title":"IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease","volume":"3","author":"Koltsida","year":"2011","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.smim.2024.101863_bib14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41590-019-0408-z","article-title":"Interferon-lambda modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus.","volume":"20","author":"Hemann","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41590-019-0345-x","article-title":"Interferon-lambda enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin.","volume":"20","author":"Ye","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-019-0182-z","article-title":"Interferon-lambda orchestrates innate and adaptive mucosal immune responses.","volume":"19","author":"Ye","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.smim.2024.101863_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"Galani","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101863_bib21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101863_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111148","article-title":"Plasmacytoid dendritic cells during COVID-19: Ally or adversary?","volume":"40","author":"Van der Sluis","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2024.101863_bib23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jaci.2017.08.032","article-title":"Plasmacytoid dendritic cells drive acute asthma exacerbations","volume":"142","author":"Chairakaki","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41586-022-04421-w","article-title":"The cGAS-STING pathway drives type I IFN immunopathology in COVID-19","volume":"603","author":"Domizio","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101863_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.smim.2024.101863_bib26","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2024.101863_bib27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.smim.2024.101863_bib28","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101863_bib29","article-title":"Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients","author":"Hadjadj","year":"2020","journal-title":"Medrxiv. Org. Ed."},{"key":"10.1016\/j.smim.2024.101863_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4864","article-title":"Pathogenic potential of interferon alphabeta in acute influenza infection","volume":"5","author":"Davidson","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2024.101863_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19619-7","article-title":"SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography","volume":"11","author":"Klein","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2024.101863_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virol.2014.04.027","article-title":"Membrane rearrangements mediated by coronavirus nonstructural proteins 3 and 4","volume":"458-459","author":"Hagemeijer","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.smim.2024.101863_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.sbi.2016.02.001","article-title":"When your cap matters: structural insights into self vs non-self recognition of 5' RNA by immunomodulatory host proteins","volume":"36","author":"Leung","year":"2016","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.smim.2024.101863_bib34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101863_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02335-21","article-title":"SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS to evade the innate immune response","volume":"12","author":"Liu","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.smim.2024.101863_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030530","article-title":"SARS-CoV-2 nucleocapsid protein targets RIG-I-Like receptor pathways to inhibit the induction of interferon response","volume":"10","author":"Oh","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.smim.2024.101863_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/v13081439","article-title":"SARS-CoV-2 N protein targets TRIM25-mediated RIG-I activation to suppress innate immunity","volume":"13","author":"Gori Savellini","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2024.101863_bib38","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.smim.2024.101863_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17665-9","article-title":"Activation and evasion of type I interferon responses by SARS-CoV-2","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2024.101863_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of Type I Interferon by SARS-CoV-2","volume":"33","author":"Xia","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2024.101863_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198074","article-title":"The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway","volume":"286","author":"Li","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.smim.2024.101863_bib42","article-title":"SARS-CoV-2 suppresses IFNbeta production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon.","volume":"17","author":"Shemesh","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2024.101863_bib43","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I\/MDA-5 signaling","volume":"5","author":"Zheng","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.smim.2024.101863_bib44","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1002\/jmv.27050","article-title":"SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I\/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways","volume":"93","author":"Han","year":"2021","journal-title":"J. Med Virol."},{"key":"10.1016\/j.smim.2024.101863_bib45","doi-asserted-by":"crossref","first-page":"28344","DOI":"10.1073\/pnas.2016650117","article-title":"SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling","volume":"117","author":"Miorin","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2024.101863_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-00208-3","article-title":"SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2","volume":"6","author":"Mu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.smim.2024.101863_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108761","article-title":"SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO","volume":"34","author":"Wu","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2024.101863_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109126","article-title":"Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities","volume":"35","author":"Hayn","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2024.101863_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108916","article-title":"Sarbecovirus ORF6 proteins hamper induction of interferon signaling","volume":"34","author":"Kimura","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2024.101863_bib50","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41423-020-00603-6","article-title":"Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon response","volume":"18","author":"Cao","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101522","article-title":"Impaired innate antiviral defenses in COVID-19: causes, consequences and therapeutic opportunities","volume":"55","author":"Galani","year":"2021","journal-title":"Semin Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib52","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1084\/jem.20181621","article-title":"Severe influenza pneumonitis in children with inherited TLR3 deficiency","volume":"216","author":"Lim","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2024.101863_bib53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.aaa1578","article-title":"Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency","volume":"348","author":"Ciancanelli","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101863_bib54","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1084\/jem.20180628","article-title":"Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency","volume":"215","author":"Hernandez","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2024.101863_bib55","first-page":"370","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101863_bib56","first-page":"6","article-title":"X-linked recessive TLR7 deficiency in \u223c1% of men under 60 years old with life-threatening COVID-19","author":"Asano","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib57","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201387","article-title":"SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4","volume":"218","author":"Onodi","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2024.101863_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","article-title":"Genetic mechanisms of critical illness in COVID-19","volume":"591","author":"Pairo-Castineira","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101863_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00205-20","article-title":"RNase L amplifies interferon signaling by inducing protein kinase R-mediated antiviral stress granules","volume":"94","author":"Manivannan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2024.101863_bib60","doi-asserted-by":"crossref","first-page":"eabo3627","DOI":"10.1126\/science.abo3627","article-title":"Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children","volume":"379","author":"Lee","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101863_bib61","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101863_bib62","first-page":"370","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.smim.2024.101863_bib63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00134-021-06392-4","article-title":"with the Amsterdam UMCC-BI: autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients","volume":"47","author":"Koning","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.smim.2024.101863_bib64","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain","volume":"41","author":"Troya","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1327","article-title":"Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients","volume":"10","author":"Goncalves","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","article-title":"Diverse functional autoantibodies in patients with COVID-19","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.smim.2024.101863_bib67","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19","volume":"99","author":"Abers","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.smim.2024.101863_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102598","article-title":"COVID-19 convalescent plasma composition and immunological effects in severe patients","volume":"118","author":"Acosta-Ampudia","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.smim.2024.101863_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj7521","article-title":"Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort","volume":"14","author":"Carapito","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2024.101863_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2024.101863_bib71","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s10875-022-01308-3","article-title":"Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19","volume":"42","author":"Eto","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"van der Wijst","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2024.101863_bib73","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/ard-2022-222549","article-title":"Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha","volume":"81","author":"Mathian","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2024.101863_bib74","first-page":"6","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","author":"Bastard","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib75","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200413119","article-title":"The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies","volume":"119","author":"Manry","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2024.101863_bib76","first-page":"eabp8966","article-title":"Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs","author":"Bastard","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2024.101863_bib77","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/jir.2023.0003","article-title":"Autoantibodies neutralizing type III interferons are uncommon in patients with severe coronavirus disease 2019 pneumonia","volume":"43","author":"Vanker","year":"2023","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.smim.2024.101863_bib78","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1056\/NEJM198610233151704","article-title":"Interferon therapy for condylomata acuminata","volume":"315","author":"Eron","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2024.101863_bib79","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2024.101863_bib80","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2024.101863_bib81","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2165\/00003495-200868090-00006","article-title":"Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection","volume":"68","author":"Keam","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.smim.2024.101863_bib82","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.smim.2024.101863_bib83","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0149-2918(04)90173-7","article-title":"Peginterferon alfa-2a: a review of approved and investigational uses","volume":"26","author":"Matthews","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.smim.2024.101863_bib84","first-page":"2489","article-title":"Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2024.101863_bib85","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.smim.2024.101863_bib86","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.smim.2024.101863_bib87","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1046-5928(03)00055-X","article-title":"Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS)","volume":"30","author":"Foser","year":"2003","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.smim.2024.101863_bib88","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1089\/107999001317205240","article-title":"Structural and biologic characterization of pegylated recombinant IFN-alpha2b","volume":"21","author":"Grace","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.smim.2024.101863_bib89","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"Bose","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"Suppl 1","key":"10.1016\/j.smim.2024.101863_bib90","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis - a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.smim.2024.101863_bib91","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0091270011407068","article-title":"A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology","volume":"52","author":"Hu","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.smim.2024.101863_bib92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1164\/rccm.201312-2235OC","article-title":"The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial","volume":"190","author":"Djukanovic","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.smim.2024.101863_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.smim.2024.101863_bib94","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/jir.2010.0066","article-title":"Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C","volume":"30","author":"Ramos","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.smim.2024.101863_bib95","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.smim.2024.101863_bib96","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jhep.2014.07.022","article-title":"A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection","volume":"61","author":"Muir","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.smim.2024.101863_bib97","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000508379","article-title":"The Role of Type I IFNs in Influenza: Antiviral Superheroes or Immunopathogenic Villains?","volume":"12","author":"Wu","year":"2020","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.smim.2024.101863_bib98","doi-asserted-by":"crossref","first-page":"1818446","DOI":"10.1080\/20016689.2020.1818446","article-title":"Chinese guidelines related to novel coronavirus pneumonia","volume":"8","author":"Qiu","year":"2020","journal-title":"J. Mark. Access Health Policy"},{"key":"10.1016\/j.smim.2024.101863_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107916","article-title":"An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial","volume":"99","author":"Alavi Darazam","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.smim.2024.101863_bib100","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2024.101863_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon beta-1b in treatment of severe COVID-19: a randomized clinical trial","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.smim.2024.101863_bib102","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.smim.2024.101863_bib103","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - Interim WHO solidarity trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2024.101863_bib104","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1111\/bcp.14898","article-title":"Interferon-alpha-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019","volume":"87","author":"Yu","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.smim.2024.101863_bib105","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-05425-5","article-title":"Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.smim.2024.101863_bib106","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijid.2021.03.015","article-title":"Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study","volume":"105","author":"Pandit","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.smim.2024.101863_bib107","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00605-2022","article-title":"Nebulised interferon-beta1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study","volume":"9","author":"Monk","year":"2023","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.smim.2024.101863_bib108","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012465","article-title":"COVID-19: lambda interferon against viral load and hyperinflammation","volume":"12","author":"Andreakos","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.smim.2024.101863_bib109","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200653","article-title":"COVID-19 and emerging viral infections: the case for interferon lambda","volume":"217","author":"Prokunina-Olsson","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2024.101863_bib110","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early treatment with pegylated interferon lambda for covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2024.101863_bib111","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMc2303519","article-title":"Pegylated interferon lambda for covid-19","volume":"388","author":"Andreakos","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532324000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532324000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:26:02Z","timestamp":1760916362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532324000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":111,"alternative-id":["S1044532324000010"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2024.101863","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2024.101863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101863"}}